The medical oncologist at Memorial Sloan Kettering Cancer Center discussed areas of research in renal cell carcinoma that he thinks should be further explored.
In an interview with CancerNetwork®, Robert J. Motzer, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, highlighted areas of research within renal cell carcinoma (RCC) which he believes should be studied further.
Transcription:
I think we’ve made tremendous headway with [immuno-oncology] combinations. I’m hoping that some of the drugs with novel mechanism of actions like [belzutifan; MK-6482], will bear fruit and advance our therapeutic options. And I think the other area that really needs to be explored is a better look and a deep dive into the underlying tumor biology and why some patients respond to 1 medication and some respond to another. Are there different targets that we can identify within the tumors? That’'\s an area now that really needs to be explored.
Frontline Chemo-Free Regimen Supported in HR+/HER2+ Breast Cancer Therapy
January 1st 2024Combining anastrozole with palbociclib, trastuzumab, and pertuzumab as a frontline therapy for hormone receptor–positive, HER2-positive breast cancer may avoid some of the toxicities associated with chemotherapy, says Amy Tiersten, MD.
Oncology On-The-Go Podcast: ASCO 2023 Recap
June 19th 2023Experts from University of California, Los Angeles Health and Mayo Clinic discuss key data presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in the gynecologic and gastrointestinal cancer spaces and how they may impact patient care.